Cutaneous leıshmanıasıs: a case serıes and narratıve revıew: cutaneous leıshmanıasıs: a case serıes

Deniz Duman Günsay; Ezgi TAN; Gülnaz Culha; Asena Çiğdem Doğramacı

doi:10.5281/zenodo.17593861

Authors

Deniz Duman Günsay Defne State Hospital
Ezgi TAN Department of Dermatology, Hatay Mustafa Kemal University,Faculty of Medicine,Hatay,Turkey
Gülnaz Culha Department of Parasitology, Hatay Mustafa Kemal University,Faculty of Medicine,Hatay,Turkey
Asena Çiğdem Doğramacı Institution: Department of Dermatology, Hatay Mustafa Kemal University,Faculty of Medicine,Hatay,Turkey

DOI:

https://doi.org/10.5281/zenodo.17593861

Keywords:

Cutaneous Leishmaniasis, Glucantime, Endemic, Refugees, Protozoan Microorganisms

Abstract

Giriş: Kutanöz leishmaniasis (KL), Leishmania türlerine ait vektör kaynaklı parazitlerin neden olduğu bir deri hastalığıdır. Genellikle kendiliğinden iyileşen ve sıklıkla iz bırakan ülseratif lezyonlarla karakterizedir. Enfekte dişi tatarcık sineğinin ısırmasıyla bulaşır. Etken mikroorganizma uzun zamandır tanımlanmış olmasına rağmen, KL, özellikle gelişmekte olan bölgelerde önemli bir halk sağlığı sorunu olmaya devam etmektedir. Özellikle endemik bölgelerden göç nedeniyle artan vaka sayısı nedeniyle tanı ve tedavi zorlukları devam etmektedir.

Olgular: Bu olgu serisi altı farklı kutanöz leishmaniasis olgusunu içermektedir. Olguların ikisi kadın, dördü erkekti. Hastalara Polimeraz Zincir Reaksiyonu (PCR), punch biyopsi, PAS/EZN boyama ve kan yayması kullanılarak tanı konuldu. Olguların tamamı, kutanöz leishmaniasis'in endemik olduğu Türkiye'nin Hatay ilinde ikamet ediyordu. Olguların üçü intramusküler glukantim tedavisi, ikisi ise intralezyonel glukantim tedavisi aldı. Glukantim tedavisini takiben tüm olgulardaki lezyonlar geriledi. Tedavi kurumumuzun etik kurulu tarafından onaylanmış ve tüm katılımcılardan aydınlatılmış onam alınmıştır.

Sonuç: Leishmaniasis bir asırdan uzun süredir bilinmesine rağmen, kontrol ve tedavisi hala karmaşıktır. Ülkemizde, özellikle endemik bölgelerden göç bağlamında artan vaka sayısı, erken teşhis ve standart tedavi protokollerinin önemini vurgulamaktadır.

References

1. Alvar J, Vélez ID, Bern C, et al. Leishmaniasis worldwide and global estimates of its incidence. PLoS One. 2012;7(5):e35671.

2. Baneth G, Solano-Gallego L. Leishmaniasis. Vet Clin North Am Small Anim Pract. 2022;52(6):1359-75.

3. Singh OP, Sundar S. Developments in diagnosis of visceral leishmaniasis in the elimination era. J Parasitol Res. 2015;2015:239469.

4. Pena HP, Belo VS, Fontes ID, et al. Histopathological findings and diagnosis of cutaneous leishmaniasis, confirmed by PCR, in an endemic region of Brazil. J Infect Dev Ctries. 2024;18(6):895-9.

5. Croft SL, Sundar S, Fairlamb AH. Drug resistance in leishmaniasis. Clin Microbiol Rev. 2006;19(1):111-26.

6. Minodier P, Parola P. Cutaneous leishmaniasis treatment. Travel Med Infect Dis. 2007;5(3):150-8.

7. Crecelius EM, Burnett MW. Cutaneous Leishmaniasis. J Spec Oper Med. 2021;21(1):113-114.

8. Volpedo G, Pacheco-Fernandez T, Holcomb EA, Cipriano N, Cox B, Satoskar AR. Mechanisms of Immunopathogenesis in Cutaneous Leishmaniasis And Post Kala-azar Dermal Leishmaniasis (PKDL). Front Cell Infect Microbiol. 2021;11:685296.

9. Volpedo G, Pacheco-Fernandez T, Holcomb EA, Cipriano N, Cox B, Satoskar AR. Mechanisms of Immunopathogenesis in Cutaneous Leishmaniasis And Post Kala-azar Dermal Leishmaniasis (PKDL). Front Cell Infect Microbiol. 2021;11:685296.

10. Özbel Y, Töz S, Muñoz C, et al. The current epidemiology of leishmaniasis in Turkey, Azerbaijan and Georgia and implications for disease emergence in European countries. Zoonoses Public Health. 2022;69(5):395-407.

11. Yentur Doni N, Gurses G, Dikme R, et al. Cutaneous Leishmaniasis due to Three Leishmania Species Among Syrian Refugees in Sanliurfa, Southeastern Turkey. Acta Parasitol. 2020;65(4):936-948.

12. Tunalı V, Özbilgin A. Knock, knock, knocking on Europe's door: Threat of leishmaniasis in Europe with a focus on Turkey. Curr Res Parasitol Vector Borne Dis. 2023;4:100150.

13. Baneth G, Solano-Gallego L. Leishmaniasis. Vet Clin North Am Small Anim Pract. 2022;52(6):1359-1375.

14. Mathison BA, Bradley BT. Review of the Clinical Presentation, Pathology, Diagnosis, and Treatment of Leishmaniasis. Lab Med. 2023;54(4):363-371.

15. Siala E, Bouratbine A, Aoun K. Mediterranean visceral leishmaniasis : update on biological diagnosis. Tunis Med. 2022;100(1):13-26.

16. Faber C, Montenegro Quiñonez C, Horstick O, Rahman KM, Runge-Ranzinger S. Indoor residual spraying for the control of visceral leishmaniasis: A systematic review. PLoS Negl Trop Dis. 2022;16(5):e0010391.

17. Firooz A, Mortazavi H, Khamesipour A, et al. Old world cutaneous leishmaniasis in Iran: clinical variants and treatments. J Dermatolog Treat. 2021;32(7):673-683.

18. de Vries HJC, Schallig HD. Cutaneous Leishmaniasis: A 2022 Updated Narrative Review into Diagnosis and Management Developments. Am J Clin Dermatol. 2022;23(6):823-840.

19. Santos RCD, Pinho FA, Passos GP, Larangeira DF, Barrouin-Melo SM. Isolation of naturally infecting Leishmania infantum from canine samples in Novy-MacNeal-Nicolle medium prepared with defibrinated blood from different animal species. Vet Parasitol. 2018;257:10-14.

20. Pena HP, Belo VS, Fontes ID, et al. Histopathological findings and diagnosis of cutaneous leishmaniasis, confirmed by PCR, in an endemic region of Brazil. J Infect Dev Ctries. 2024;18(6):895-899.

21. Mazire P, Agarwal V, Roy A. Road-map of pre-clinical treatment for Visceral Leishmaniasis. Drug Dev Res. 2022;83(2):317-327.

22. Koussayer Z, Koussayer J, Tyring SK. An Update on the Clinical Management of Cutaneous Leishmaniasis. Skin Therapy Lett. 2025;30(1):5-9.

23. Minodier P, Parola P. Cutaneous leishmaniasis treatment. Travel Med Infect Dis. 2007;5(3):150-158.

24. Pradhan S, Schwartz RA, Patil A, Grabbe S, Goldust M. Treatment options for leishmaniasis. Clin Exp Dermatol. 2022;47(3):516-521.

25. Linquest LA, Hickham LC, Richardson BJ, Hickham PR. Successful Treatment of Cutaneous Leishmaniasis With Cryotherapy. Cureus. 2023;15(7):e41871.

26. Silva H, Liyanage A, Deerasinghe T, et al. Therapeutic Response to Thermotherapy in Cutaneous Leishmaniasis Treatment Failures for Sodium Stibogluconate: A Randomized Controlled Proof of Principle Clinical Trial. Am J Trop Med Hyg. 2021;104(3):945-950.

27. Slavin YN, Asnis J, Häfeli UO, Bach H. Metal nanoparticles: understanding the mechanisms behind antibacterial activity. J Nanobiotechnology. 2017;15(1):65.

28. Zein R, Alghoraibi I, Soukkarieh C, Alahmad A. Investigation of Cytotoxicity of Biosynthesized Colloidal Nanosilver against Local Leishmania tropica: In Vitro Study. Materials (Basel). 2022;15(14):4880.

29. Alemzadeh E, Karamian M, Abedi F, Hanafi-Bojd MY. Topical treatment of cutaneous leishmaniasis lesions using quercetin/ Artemisia-capped silver nanoparticles ointment: Modulation of inflammatory response. Acta Trop. 2022;228:106325.

30. Ge X, Cao Z, Chu L. The Antioxidant Effect of the Metal and Metal-Oxide Nanoparticles. Antioxidants (Basel). 2022;11(4):791.

31. Almeida TF, Palma LC, Mendez LC, Noronha-Dutra AA, Veras PS. Leishmania amazonensis fails to induce the release of reactive oxygen intermediates by CBA macrophages. Parasite Immunol. 2012;34(10):492-498.

32. Islam A, Ain Q, Munawar A, et al. Reactive oxygen species generating photosynthesized ferromagnetic iron oxide nanorods as promising antileishmanial agent. Nanomedicine (Lond). 2020;15(8):755-771.

Cutaneous leıshmanıasıs: a case serıes and narratıve revıew